Automate Your Wheel Strategy on LNTH
With Tiblio's Option Bot, you can configure your own wheel strategy including LNTH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LNTH
- Rev/Share 22.1941
- Book/Share 17.0294
- PB 3.0923
- Debt/Equity 0.5275
- CurrentRatio 4.2902
- ROIC 0.1716
- MktCap 3580574572.0
- FreeCF/Share 6.9063
- PFCF 7.5669
- PE 13.3137
- Debt/Assets 0.2909
- DivYield 0
- ROE 0.2357
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LNTH | Truist | Buy | Hold | -- | $63 | Aug. 12, 2025 |
| Initiation | LNTH | Goldman | -- | Buy | -- | $143 | Dec. 18, 2024 |
| Initiation | LNTH | Redburn Atlantic | -- | Buy | -- | $175 | Sept. 3, 2024 |
News
Lantheus Announces Alzheimer's Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
BEDFORD, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity.
Read More
Lantheus Completes Acquisition of Evergreen Theragnostics
Published: April 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. (“Evergreen”), a clinical-stage radiopharmaceutical company. The acquisition was first announced on January 28, 2025.
Read More
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Positive
Lantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, have diversified Lantheus' pipeline, targeting new markets like Alzheimer's diagnostics and oncology therapeutics. Pylarify's potential patent expiration in 2026 poses a risk, but management is actively seeking to extend protections and diversify revenue streams.
Read More
Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q4 2024 - Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Amanda Morgan - Chief Commercial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Financial Group Richard Newitter - Truist Securities Paul Choi - Goldman Sachs Matt Taylor - Jefferies Yuan Zhi - B. Riley Larry Solow - CJS Securities Justin Walsh - Jones Trading Andy Hsieh - William Blair John Vandermosten - Zacks Kemp Dolliver - Brookline Capital …
Read More
About Lantheus Holdings, Inc. (LNTH)
- IPO Date 2015-06-25
- Website https://www.lantheus.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Brian A. Markison
- Employees 808